img

Acute Kidney Injury Treatment Market by Product (Dialysis, Drug Therapy), Injury (Pre-renal Injury, Intrinsic Renal Injury, Post-renal Injury), Distribution Channel (Hospitals, Ambulatory Surgical Centers) & Region for 2024-2031


Published on: 2024-08-03 | No of Pages : 320 | Industry : latest updates trending Report

Publisher : MIR | Format : PDF&Excel

Acute Kidney Injury Treatment Market by Product (Dialysis, Drug Therapy), Injury (Pre-renal Injury, Intrinsic Renal Injury, Post-renal Injury), Distribution Channel (Hospitals, Ambulatory Surgical Centers) & Region for 2024-2031

Acute Kidney Injury Treatment Market Valuation – 2024-2031  

The Acute Kidney Injury (AKI) therapy market is expanding due to rising prevalence of kidney-related illnesses and increasing awareness. Dialysis, medicine and supportive care are among the most important treatments. Technological developments and enhanced diagnostic methods both contribute to market growth. This is likely to enable the market size surpass USD 1.51 Billion valued in 2024 to reach a valuation of around USD 2.56 Billion by 2031.

Rising chronic disorders such as diabetes and hypertension are propelling the AKI therapy market. However, high treatment costs and low awareness in developing countries provide obstacles. Government initiatives and improvements to healthcare infrastructure are critical for market growth, as is continued research into breakthrough therapeutics. The rising demand for acute kidney injury treatment is enabling the market grow at a CAGR of 6.85% from 2024 to 2031.

Acute Kidney Injury Treatment MarketDefinition/ Overview

Acute Kidney Injury (AKI) treatment consists of addressing the underlying cause, maintaining fluid balance and supporting kidney function. This involves drugs, dialysis if necessary and monitoring electrolyte and waste levels to avoid problems and enhance recovery.

Acute kidney injury (AKI) treatment focuses on addressing the underlying cause, restoring kidney function and avoiding complications. Common interventions include hydration control, electrolyte balance, medicine and dialysis. Early diagnosis and treatment are critical for avoiding permanent kidney damage and improving patient outcomes.

Advances in early detection, customized therapeutics and regenerative medicine will shape the treatment of Acute Kidney Injury (AKI). Innovations such as biomarker-based diagnostics and stem cell therapies are projected to enhance patient outcomes by slowing the progression of chronic kidney disease and improving overall kidney function.

What's inside a
industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Will Rising Prevalence of Chronic Diseases Boost the Growth of Acute Kidney Injury Treatment Market?

The rising incidence of chronic disorders including diabetes and hypertension is a major driver driving the acute kidney injury (AKI) therapy market. According to the Centers for Disease Control and Prevention (CDC), around 37 million US individuals have chronic kidney disease (CKD), which is frequently undetected in the early stages.

According to the NIDDK, AKI affects 5-7% of hospitalized patients and up to 20% of critically ill patients acquire AKI. The USRDS 2020 Annual Data Report cites a rise in CKD prevalence among Medicare beneficiaries, while the National Kidney Foundation emphasizes the significant impact of diabetes and hypertension on CKD patients. Furthermore, the prevalence of AKI has increasing dramatically, highlighting the urgent need for better treatments.

Will High Cost of Treatment Hamper the Acute Kidney Injury Treatment Market?

The high cost of treatment for acute kidney injury (AKI) may limit market expansion. A study published in the National Library of Medicine found that the average hospitalization cost for AKI patients is $24,896, compared to $13,425 for individuals without AKI. This $11,471 additional cost associated with AKI may be a considerable financial burden for people and healthcare systems.

Furthermore, the high costs associated with modern diagnostic and therapeutic approaches may impede access to timely and effective care. This economic constraint may hinder market growth, especially in areas with inadequate healthcare resources or insufficient insurance coverage.

Category-Wise Acumens

Will Decreasing Blood Flow to the Kidneys Drive the Injury Segment?

A decrease in blood supply to the kidneys will cause the acute kidney injury (AKI) phase. Reduced renal perfusion is the major cause of AKI, which is frequently caused by severe dehydration, shock, or heart failure. When blood flow is reduced, the kidneys cannot filter waste adequately, resulting in kidney injury. This pathophysiological mechanism contributes significantly to AKI cases, emphasizing the need of targeting decreased renal perfusion in therapeutic efforts.

The growing awareness and emphasis on controlling and avoiding diseases that cause reduced blood flow to the kidneys is expected to fuel growth in the AKI therapy segment. Early detection and intervention are critical for reducing harm and improving patient outcomes, which encourages the development of focused medicines and diagnostic technologies in this area.

Will Increasing Demand for Managing Kidney Failure by Removing Waste Drive the Dialysis Segment?

The dialysis segment will be driven by an increase in demand for waste removal to manage renal failure. As kidney function deteriorates, dialysis becomes necessary to accomplish the crucial job of removing waste and excess fluid from the blood.

The rise in chronic renal disease, diabetes and hypertension, all of which contribute to kidney failure, emphasizes the importance of effective dialysis solutions. Advances in dialysis technology, as well as increasing awareness of its benefits, help to fuel this trend. With an increasing patient population requiring dialysis, driven by the increasing prevalence of kidney failure, demand for dialysis treatments is likely to rise further, propelling innovation and market expansion in this sector.

Gain Access into Acute Kidney Injury Treatment Market Report Methodology

Country/Region-wise Acumens

Will High Prevalence of Chronic Diseases Drive the Market in North America?

The rising prevalence of chronic diseases will propel the AKI therapy market in North America. Chronic illnesses common in the region, such as diabetes and hypertension, are important risk factors for acute kidney injury. With millions of people impacted by these disorders, there is an increasing demand for better AKI treatments.

North America’s modern healthcare system and high level of care encourage the use of novel medicines and technologies to manage and treat AKI. Furthermore, large investments in R&D, together with increasing awareness of kidney health, contribute to market growth. As chronic disease rates rise, the demand for AKI therapies will stay high, fueling market growth in North America.

Will Increasing Awareness of Kidney Diseases Drive the Market in Asia Pacific Region?

The acute kidney injury (AKI) treatment market in Asia-Pacific will grow due to increasing awareness of kidney illnesses. Growing public and healthcare professional awareness of the prevalence, risk factors and implications of kidney disease is resulting in earlier diagnosis and more proactive treatment. This increasing awareness fuels demand for new diagnostic tools and treatment choices.

Furthermore, educational initiatives and government health programs aiming at improving kidney health help to drive market growth. As the public gets more educated about kidney disease prevention and management, there will be a greater uptake of AKI treatments, driving market growth. Improved awareness contributes to the overall development of healthcare infrastructure and encourages investment in medical technologies, increasing regional market growth.

Competitive Landscape

The acute kidney injury treatment market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the acute kidney injury treatment market include

  • Baxter International, Inc.
  • Fresenius Medical Care AG & Co KGaA
  • Braun Melsungen AG
  • Angion Biomedica Corp
  • AM-Pharma
  • Quark Pharmaceuticals, Inc.
  • Asahi Kasei Medical Co Ltd
  • LG Chem

Acute Kidney Injury Treatment Market Latest Developments

  • In March 2021, B. Braun Avitum AG, a major manufacturer of medical equipment and pharmaceutical products and services and CytoSorbents Corporation, a critical care immunotherapy leader commercializing its CytoSorb blood purification technology to treat fatal inflammation, announced the partnership launched a global co-marketing agreement to promote the usage of CytoSorb.
  • In March 2021, Critical Path Institute (C-Path), a nonprofit organization, announced the commencement of the Acute Kidney Injury (AKI) Project in partnership with the US Food and Drug Administration. The business proposes creating prognostic tools to better anticipate and identify drug-induced kidney damage (DIKI).
  • In November 2020, Vifor Pharma, a Swiss medicine maker, agreed to pay Angion Biomedica up to USD 80.0 Million for rights to experimental kidney drug ANG-3777

Report Scope

Report AttributesDetails
Study Period

2021-2031

Growth Rate

CAGR of ~6.85% from 2024 to 2031

Base Year for Valuation

2024

Historical Period

2021-2023

Forecast Period

2024-2031

Quantitative Units

Value in USD Billion

Report Coverage

Historical and Forecast Revenue Forecast, Historical and Forecast Volume, Growth Factors, Trends, Competitive Landscape, Key Players, Segmentation Analysis

Segments Covered
  • Product
  • Injury
  • Distribution Channel
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Key Players

Baxter International, Inc., Fresenius Medical Care AG & Co KGaA, Braun Melsungen AG, Angion Biomedica Corp, AM-Pharma, Quark Pharmaceuticals, Inc., Asahi Kasei Medical Co Ltd, LG Chem

Customization

Report customization along with purchase available upon request

Acute Kidney Injury Treatment Market, By Category

Product

  • Dialysis
    • Intermittent Hemodialysis
    • Continuous Renal Replacement Therapy (CRRT)
    • Sustained Low-Efficiency Dialysis (SLED)
  • Drug Therapy
    • Antibiotics
    • Diuretics
    • Immunosuppressive Agents

Injury

  • Pre-renal Injury
  • Intrinsic Renal Injury
  • Post-renal Injury

Distribution Channel

  • Hospitals
  • Ambulatory Surgical Centers

Region

  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East & Africa

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.

Pivotal Questions Answered in the Study

Some of the key players leading in the acute kidney injury treatment market include the Baxter International, Inc., Fresenius Medical Care AG & Co KGaA, Braun Melsungen AG, Angion Biomedica Corp, AM-Pharma, Quark Pharmaceuticals, Inc., Asahi Kasei Medical Co Ltd, LG Chem.
The rising incidence of chronic conditions such as diabetes and hypertension, which raise the risk of acute kidney damage (AKI), is the key driver of the market. Furthermore, advances in diagnostic technologies and increasing awareness of early detection and treatment are driving market expansion.
The acute kidney injury treatment market is estimated to grow at a CAGR of 6.85% during the forecast period.
The acute kidney injury treatment market was valued at around USD 1.51 Billion in 2024.
The sample report for the Acute Kidney Injury Treatment Market can be obtained on demand from the website. Also, 24*7 chat support & direct call services are provided to procure the sample report.

Table of Content

To get a detailed Table of content/ Table of Figures/ Methodology Please contact our sales person at ( chris@marketinsightsresearch.com )
To get a detailed Table of content/ Table of Figures/ Methodology Please contact our sales person at ( chris@marketinsightsresearch.com )